Company Filing History:

25 out of 112

Orion-yhtyma Oy

Orion Corporation/orion Pharmaceutica

patent

Years Active: 1981-2000

Loading Chart...

28 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 6121303 - Pharmacologically active catechol derivatives (2000-09-19),

2. 5889037 - Pharmacologically active catechol derivatives (1999-03-30),

3. 5614541 - Pharmacologically active catechol derivatives (1997-03-25),

4. 5569657 - (-)-[[4-(1,4,5,6-tetrahydro-4-m (1996-10-29),

5. 5512572 - Anti-ischemic medicament (1996-04-30),

6. 5512571 - (-) (1996-04-30),

7. 5446194 - Pharmacologically active catechol derivatives (1995-08-29),

8. 5424428 - ( (1995-06-13),

9. 5382699 - Method for the preparation of 3,4-dihydroxy-5-nitrobenzaldehyde (1995-01-17),

10. 5362733 - Pharmacologically active catechol derivatives (1994-11-08),

11. 5356923 - 1-hydroxy-4(3-cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidone and (1994-10-18),

12. 5292771 - Substituted .beta.-diketones and their use (1994-03-08),

13. 5288750 - Substituted .beta.-diketones (1994-02-22),

14. 5283352 - Pharmacologically active compounds, methods for the preparation thereof (1994-02-01),

15. 5185370 - Substituted .beta.-diketones and their use (1993-02-09),

Title: The Innovative Contributions of Erkki J Honkanen in Pharmacology

Introduction: Erkki J Honkanen, based in Vantaa, Finland, is a distinguished inventor known for his significant contributions to the field of pharmacology. With an impressive portfolio of 28 patents, he has made remarkable strides in developing compounds that are essential in therapeutic applications.

Latest Patents: Among his latest innovations are pharmacologically active catechol derivatives. These compounds are characterized by a formula that includes specific substituents like nitro, halogeno, or cyano groups. Additionally, the compounds feature groups that can vary from hydrogen to various alkyl, cycloalkyl, or aryl groups. These derivatives play a crucial role in preventing or treating tissue damage induced by lipid peroxidation, significantly impacting healthcare through the potential creation of new pharmaceutical compositions.

Career Highlights: Throughout his career, Erkki J Honkanen has worked with reputable organizations, including Orion-yhtyma Oy and Orion Corporation, where he honed his expertise in medicinal chemistry. His innovative work has laid the groundwork for developing new therapies, reinforcing his status as a leader in the field.

Collaborations: Honkanen has collaborated with other notable researchers, including Reijo J Backstrom and Aino K Pippuri. These collaborative efforts have fostered advancements in pharmacological research and development, allowing for the exchange of ideas and further innovation.

Conclusion: Erkki J Honkanen's contributions to pharmacology through his innovative patents and collaborations represent a significant advancement in the field. His work in developing pharmacologically active catechol derivatives showcases the power of innovation in medicine, highlighting how dedicated inventors can influence the future of healthcare.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com